Study on Irinotecan and Carboplatin for Lung Cancer
Author Information
Author(s): Yamada M, Kudoh S, Fukuda H, Nakagawa K, Yamamoto N, Nishimura Y, Negoro S, Takeda K, Tanaka M, Fukuoka M
Primary Institution: Osaka City University Medical School
Hypothesis
The study aims to evaluate the maximum tolerated dose, recommended dose, and toxicity profile of weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Conclusion
The study concluded that the major toxicity of this regimen was pneumonitis, and it may be effective against unresectable non-small cell lung cancer.
Supporting Evidence
- The maximum tolerated dose of irinotecan was found to be 60 mg/m².
- The recommended dose of irinotecan was determined to be 50 mg/m².
- The overall objective response rate was 60.0%, with three patients achieving complete remission.
Takeaway
Doctors tested a new treatment for lung cancer and found that it can help some patients, but it can also cause serious side effects like lung problems.
Methodology
Patients received weekly irinotecan plus carboplatin for 4 weeks and thoracic radiotherapy for 6 weeks, with dose escalation of irinotecan.
Limitations
The study had a small sample size and was limited to patients with specific performance statuses.
Participant Demographics
Median age was 62 years, with 28 patients having a performance status of 0-1 and 12 with stage IIIA disease.
Statistical Information
Confidence Interval
95% confidence interval 41.4–78.6%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website